試す 金 - 無料
The MBA evolution: Depth over breadth
Business Standard
|January 13, 2026
While the general MBA remains a prestigious "gold standard," evolving industries now demand deeper functional expertise. From data analytics to digital marketing, specialised programs offer targeted skill sets that align with modern roles
-
For decades, the general MBA has been viewed as the gold standard of management education. It promises versatility, leadership exposure, and access to a wide range of career opportunities.
As industries evolved, however, business challenges became more complex, data-driven, and function-specific. In response, business schools expanded their offerings to include specialised programs in marketing, business analytics, operations, supply chain management, and other focused domains. Today, for many aspirants, the crucial question is no longer whether to pursue an MBA, but which kind of MBA makes the most sense.
In an environment where depth often outweighs breadth, a specialised MBA can sometimes deliver greater career alignment and impact than a general management degree. Understanding when and why this shift is appropriate is essential for making a strategic education decision.
The traditional general MBA was designed for an era when managers were expected to oversee multiple functions with limited technological complexity. Decision-making relied heavily on experience and intuition, and departmental boundaries were more rigid. In contrast, modern organisations operate in fast-moving, interconnected ecosystems where technology, data, and specialised expertise drive outcomes.
Marketing now demands deep understanding of digital platforms, consumer analytics and brand storytelling. Operations require mastery over supply chains, process optimisation and risk management. Analytics has emerged as a core strategic function, transforming raw data into business intelligence. In such contexts, specialised knowledge is not merely an advantage - it is often a prerequisite.
このストーリーは、Business Standard の January 13, 2026 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Business Standard からのその他のストーリー
Business Standard
Labour Codes impact: HCL tech profit slips 11%
Q3 top line beats Street estimates, bottom line misses expectations
2 mins
January 13, 2026
Business Standard
New labour Codes, restructuring weigh on TCS earnings
Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.
1 min
January 13, 2026
Business Standard
Black drives the thrill for car buyers
Sees a surge in yearly sales, while white remains practical 'utility king'
2 mins
January 13, 2026
Business Standard
CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS
Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be
2 mins
January 13, 2026
Business Standard
China’s PVC rethink to help India pipe makers
Supply likely to tighten after S-PVC rebate withdrawal
2 mins
January 13, 2026
Business Standard
Responsible growth
India must ensure data centres are sustainable
2 mins
January 13, 2026
Business Standard
India’s GenZ is full of creativity: PM
Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.
1 min
January 13, 2026
Business Standard
Iran wants to negotiate after threats to attack, says Trump
At least 572 killed in protests; Tehran says situation ‘under full control’
2 mins
January 13, 2026
Business Standard
Insurers knock on Irdai door for clarity on director overlap ban
CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY
2 mins
January 13, 2026
Business Standard
Delhi HC allows Zydus to sell generic version of cancer drug
Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.
1 min
January 13, 2026
Listen
Translate
Change font size
